A Phase 4 interventional study of Buventol® Easyhaler® 200 µg/inhalation dmDPI and Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI in Asthma, sponsored by Orion Corporation, Orion Pharma. Completed at 2 sites in Finland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-05.
Sponsored by Orion Corporation, Orion Pharma · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Asthma by Orion Corporation, Orion Pharma — none open to participants now, none under way, none of them phase 3. Asthma · Orion Corporation, Orion Pharma.
Among the 21 studies in Asthma by Orion Corporation, Orion Pharma, this one is the 3rd largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2021, is one of 2 in phase 4, and was the 21st registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →None of the 21 studies in Asthma by Orion Corporation, Orion Pharma is open now. The open studies under Asthma, anywhere →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 1 · Phase 3 1 · Phase 4 2
First in 2009; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 180 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 72 across the 19 interventional studies, 130 across the 2 observational. Of the 21 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Orion Corporation, Orion Pharma is the lead sponsor of 101 studies on the registry; 3 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in Asthma by Orion Corporation, Orion Pharma, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study compares Buventol® Easyhaler® and Bufomix® Easyhaler® to the current standard treatment during methacholine challenge test. The trial will also provide inspiratory flow profile data for Easyhaler inhaler.
This trial is designed to provide a further evidence for the use of Easyhaler in diagnostic bronchial challenge tests and on the use of Easyhaler inhaler during obstructive event.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects not eligible for methacholine challenge test for example for any of the following reasons:
Subjects who have used the following treatments before the study visit:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
400 μg of salbutamol from Buventol Easyhaler is administered as two inhalations.
Drug: Buventol® Easyhaler® 200 µg/inhalation dmDPI
320 μg of budesonide and 9 μg of formoterol are administered from Bufomix Easyhaler as two inhalations.
Drug: Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI
400 μg of salbutamol from Ventoline Evohaler is administered via Volumatic spacer as four inhalations.
Drug: Ventoline® Evohaler® 100 µg/inhalation pMDI
Two doses will be administered
Also known as: Salbutamol 200 µg/dose dmDPI
Two doses will be administered
Also known as: Budesonide/formoterol 160/4.5 µg/inhalation dmDPI
Four doses will be administered via Volumatic spacer
Also known as: Salbutamol 100 µg/dose MDI
Forced expiratory volume in one second (FEV1)
Mean change in FEV1 from post-diluent to FEV1 after the first dose of reliever.
Time frame: 10 minutes
Number of subjects who recover from bronchoconstriction after first dose
Proportion of the subjects who recover to FEV1 \> -10% compared to post-diluent FEV1 after first dose of reliever.
Time frame: 10 minutes
Forced expiratory volume in one second (FEV1)
Relative recovery of FEV1 after the study treatment dosing when compared to post-diluent FEV1.
Time frame: 10 minutes
Number of subjects who recover from bronchoconstriction after second dose
Proportions of subjects reaching FEV1 \> -10% of post-diluent value after second dose of reliever.
Time frame: 20 minutes
Number of patients needing medical attention
Proportion of subjects needing medical attention after study treatment
Time frame: After study treatment administration until study completion (an average of 2.5 hours)
Inhalation profile via Easyhaler
Time-inspiratory flow -curve via Easyhaler measured with spirometer.
Time frame: Before methacholine challenge and 10 minutes after the subject experiences FEV1 drop ≥ 20% compared to post-diluent spirometry
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2021 to primary completion in Jun 2023, 19 months.
Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 19 months is close to that.
Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Orion Corporation, Orion Pharma →